Vertex Pharmaceuticals

About Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that is committed to transforming the lives of people with serious diseases. Founded in 1989, the company has pioneered innovative therapies for cystic fibrosis and other genetic disorders. With a strong focus on research and development, Vertex aims to discover and develop breakthrough medicines that address unmet medical needs.

The company’s flagship product, Kalydeco, was the first drug approved to treat the underlying cause of cystic fibrosis, marking a significant milestone in the treatment of this condition. Vertex continues to expand its portfolio with additional therapies that target specific mutations in the CFTR gene, providing hope to patients worldwide.

In addition to cystic fibrosis, Vertex is also exploring treatments for other serious diseases, including sickle cell disease and beta-thalassemia. The company employs cutting-edge science and technology to advance its research initiatives, collaborating with leading academic institutions and industry partners.

Vertex is headquartered in Boston, Massachusetts, but has a growing presence in the UK, where it is dedicated to fostering innovation and supporting local communities. The company values diversity and inclusion, striving to create a workplace that reflects the diverse populations it serves.

With a commitment to sustainability, Vertex actively engages in initiatives that promote environmental responsibility and ethical practices. The company believes in the importance of corporate social responsibility and invests in programs that enhance access to healthcare and education.

As Vertex Pharmaceuticals continues to grow, it remains focused on its mission to deliver transformative therapies that improve the quality of life for patients around the globe.